Considering potential safety issues, the feasibility and possible implications of the therapeutic modulation of IL‐33 signalling, which is known to act cardioprotective,21, 22, 23, 24 are currently discussed.58 As statins and BPs represent widely used and standardised classes of drugs for primary and secondary prevention of cardiovascular disease, our results might have impact also in the clinical setting. The gene discussed is IL33; the disease is cardiovascular disorder.